Another group showed that treating mice with an anti-tumor antibody fused to IFNβ increased clearance of antibody-resistant tumor cells by increasing cross presentation by tumor-infiltrating DCs and activation of CD8+ T cells (253). This evidence concerns the gene IFNB1 and neoplasm.